OBJECTIVES: The @entity4783 / @entity1510 combination is used to treat the chronic relapsing disorder of @entity4784 . Adequate dosing levels are important to control cravings, prevent @entity3347 , and maintain @entity1 in treatment. The objective of this study was to estimate the impact of dosing on treatment persistence, resource utilization, and total direct health care costs. METHODS: A retrospective cohort analysis was performed using administrative claims extracted from the MarketScan and Clinformatics databases from January 2007 to June and November 2012. @entity1 initiating treatment with @entity4783 / @entity1510 were classified into 2 groups based on the prescribed average dose over the entire treatment period and matched by multiple criteria. The threshold for differentiating the dosing groups was set at 15 and 15.7 mg/day for publicly and privately insured @entity1 , respectively. Resource utilization and related costs were calculated over the 12-month period after the treatment initiation. RESULTS: @entity1 characteristics at baseline were considerably different between the privately and publicly insured @entity1 . Publicly insured @entity1 were slightly younger (33.1 vs 34.3 years old for privately insured) and had a higher prevalence of @entity146 (70.9% vs 64.9%). In both groups, @entity1 treated with higher doses (> 15 mg and > 15.7 mg per day for publicly and privately insured @entity1 , respectively) had lower risk of discontinuation (public: 11% lower; private: 9% lower) and lower probability of a @entity146 hospitalization than @entity1 treated with lower doses (public: 17% lower; private: 41% lower). Total costs were comparable between the 2 groups (public:  14 600; private:  21 000) despite the expected higher cost of pharmacy in the higher-dose group. CONCLUSIONS: Treatment with higher doses of @entity4783 / @entity1510 was associated with a longer time to treatment discontinuation, less resource use, and lower total medical costs despite higher pharmacy acquisition cost.

Analysis of XXXX / @entity1510 dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient'] @entity3347 :: ('MESH:D013375', 'Disease') :: ['withdrawal syndrome'] @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorders', 'psychiatric'] @entity4784 :: ('MESH:D009293', 'Disease') :: ['opioid dependence'] @entity4783 :: ('MESH:D002047', 'Chemical') :: ['buprenorphine'] @entity1510 :: ('MESH:D009270', 'Chemical') :: ['naloxone']
@entity4783 :: (MESH:D002047,Chemical) :: ['buprenorphine']
